Drug Profile
NDV HUJ
Alternative Names: OV-001; TV-7000Latest Information Update: 11 Aug 2011
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 11 Jul 2006 Final results from a phase I/II clinical trial in patients with glioblastoma multiforme have been added to the adverse events and Cancer therapeutic trials sections
- 26 Jul 2005 OVCure is now called Theravir Management
- 07 Jul 2004 Phase-I/II clinical trials in Glioblastoma in Israel (IV-infusion)